Therapeutic Potential of Marine Natural Products in Inflammatory Bowel Disease
A special issue of Marine Drugs (ISSN 1660-3397).
Deadline for manuscript submissions: closed (31 May 2022) | Viewed by 320
Special Issue Editors
Interests: pharmacology; inflammation; cancer; colon; skin; polyphenols; carotenoids; microalgae; probiotics
Special Issues, Collections and Topics in MDPI journals
Interests: marine microalgae; inflammation; oxylipins; inflammatory bowel disease; colon cancer; inflammatory skin diseases
Special Issues, Collections and Topics in MDPI journals
Special Issue Information
Dear Colleagues,
Inflammatory bowel disease (IBD), encompassing ulcerative and Crohn’s disease, is characterized by chronic and relapsing intestinal inflammation. These inflammatory conditions are multifactorial and are produced by interactions between genetic, environmental, and immune factors. Although the etiology of IBD is still unclear, an aberrant innate immune response against external and internal threatening factors has been suggested to play a crucial role in the pathogenesis of IBD. In addition, accumulating evidence suggests that changes in the composition of the microbiota, called dysbiosis, may have a crucial role in IBD pathogenesis. Current IBD treatments include amino-salicylates, corticosteroids, immunosuppressants, and, recently, biological agents. Since these therapies have limited results with many side effects, many researchers have aimed to find new strategies to control symptoms and prevent relapses. In this line, the marine environment represents a large source to isolate bioactive compounds from bacteria, cyanobacteria, fungi, algae, or small invertebrates such as sponges, tunicates, bryozoans, and mollusks. This Special Issue in Marine Drugs will cover the use of marine compounds for the treatment of IBD. We invite researchers to submit their papers (reviews or original articles) reporting evidence of the role of marine products in cellular and animal models, as well as the latest advances in clinical trials. In particular, works that evaluate the molecular mechanisms of these compounds are especially encouraged.
Prof. Dr. Elena Talero
Dr. Javier Ávila-Román
Guest Editors
Manuscript Submission Information
Manuscripts should be submitted online at www.mdpi.com by registering and logging in to this website. Once you are registered, click here to go to the submission form. Manuscripts can be submitted until the deadline. All submissions that pass pre-check are peer-reviewed. Accepted papers will be published continuously in the journal (as soon as accepted) and will be listed together on the special issue website. Research articles, review articles as well as short communications are invited. For planned papers, a title and short abstract (about 100 words) can be sent to the Editorial Office for announcement on this website.
Submitted manuscripts should not have been published previously, nor be under consideration for publication elsewhere (except conference proceedings papers). All manuscripts are thoroughly refereed through a single-blind peer-review process. A guide for authors and other relevant information for submission of manuscripts is available on the Instructions for Authors page. Marine Drugs is an international peer-reviewed open access monthly journal published by MDPI.
Please visit the Instructions for Authors page before submitting a manuscript. The Article Processing Charge (APC) for publication in this open access journal is 2900 CHF (Swiss Francs). Submitted papers should be well formatted and use good English. Authors may use MDPI's English editing service prior to publication or during author revisions.
Keywords
- inflammatory bowel disease
- marine compounds
- anti-inflammatory molecules
- immune response
- bioactivity
- microbiota
